FDA approves Impax's AB rated generic Concerta Extended-Release Tablets CII

Company expects to launch by the end of the year.

Impax Laboratories has received an AB therapeutic equivalent rating and final FDA approval on its Abbreviated New Drug Application (ANDA) for a generic version of Concerta (methylphenidate hydrochloride) Extended-Release tablets USP CII, 18, 27, 36 and 54 mg.

"Approval of our AB-rated generic version of Concerta further demonstrates the capabilities of Impax's R&D organization," said Paul Bisaro, President and Chief Executive Officer of Impax. "We are preparing for launch including working to secure API quota and currently expect to launch by the end of this year. As a result, we don't anticipate sales of generic Concerta to meaningfully impact our earnings in 2017."

Methylphenidate hydrochloride extended-release tablets had US sales of approximately $1.8 billion, according to IMS Health for the 12 months ending May 2017.

Methylphenidate hydrochloride extended-release tablets, are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65.

Related News

News Patients vs Pharma – who will the Inflation Reduction Act affect the most?

The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.

11 Dec 2023
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?

In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.

25 Oct 2023
News CPHI Barcelona Annual Report illuminates industry trends for 2024

The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke...

23 Oct 2023
News Which 10 drugs are open to price negotiation with Medicare in the USA?

The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA).

5 Sep 2023
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state

Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.

28 Jun 2023
News 10 Major Drug Approvals So Far in 2023

Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...

28 Jun 2023
News Detecting Alzheimer's disease with a simple lateral flow test

A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts.

16 Jun 2023
News CPHI Podcast Series: outsourcing and manufacturing trends

Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.

14 Jun 2023